1. Pink Sheet

Wave Chasing Huntington’s Accelerated Approval Based On Caudate Atrophy Surrogate

 
• By Alaric DeArment

The biotech plans a pivotal trial that would support accelerated approval of the Takeda-partnered antisense oligonucleotide, WVE-003, and will discuss it with regulators before the end of the year.

Wave believes a registrational trial with about 150 patients could last 12 to 18 months. • Source: Shutterstock

Wave Life Sciences Ltd. expects to pitch using caudate atrophy as a surrogate endpoint to support accelerated approval of its WVE-003 in Huntington's disease to regulators by the end of the year.

Key Takeaways

  • Wave announced positive efficacy data for WVE-003 in Huntington’s disease, with statistically significant reductions in mutant huntingtin protein and promising imaging biomarker data.

The Cambridge, MA-based biotech's case may be helped by positive Phase Ib/IIa efficacy data, although potential safety concerns about neurofilament...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

EU Countries Rally Behind Novel Pathway For Combined Drug/IVD Trials

 
• By Vibha Sharma

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 
• By Eliza Slawther

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.